Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136760 · ClinicalTrials.gov registry record · Phase 2
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
A Phase 2 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00136760: Completed Phase 2 study, sponsored by Brown University.
NCT00136760 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 57 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136760, a Phase 2 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.
Primary Outcome
Urinary Cotinine levels at Week 4 (average of last 3 study visits)
Interventions
- DRUG Bupropion
- DRUG Contingent reinforcement plus placebo
- DRUG non-contingent reinforcement plus bupropion
- DRUG Non-contingent reinforcement plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
What the finished NCT00136760 record still lists
NCT00136760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 4 interventions - of which Bupropion is the first listed.
NCT00136760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00136760 about?
NCT00136760 is a clinical study titled "Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia". There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.
What is the current status of trial NCT00136760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2003-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00136760?
The interventions under investigation include: Bupropion (DRUG), Contingent reinforcement plus placebo (DRUG), non-contingent reinforcement plus bupropion (DRUG), Non-contingent reinforcement plus placebo (DRUG).
Who is sponsoring clinical trial NCT00136760?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00136760's enrollment target sits among peer trials
57 1141st of 2000 higher than 855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia